Dopamine
From DrugPedia: A Wikipedia for Drug discovery
Dopamine Pubchem(681)
One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action.
Therapeutic Indications
- Hypotension
- Parkinson Disease
Therapeutic Uses
- cns agent
- cardiovascular agent
KEGG Pathway(C03758,D07870)
- Tyrosine metabolism
- Indole and ipecac alkaloid biosynthesis
- Alkaloid biosynthesis I
- Neuroactive ligand-receptor interaction
- Gap junction
- Parkinson's disease
Activity Antihypotensive,Cardiac stimulant, cardiotonic
| MMDB ID | PDB ID | Reference |
|---|---|---|
| 34790 | 2A3R | Lu JH, Li HT, Liu MC, Zhang JP, Li M, An XM, Chang WRCrystal structure of human sulfotransferase SULT1A3 in complex with dopamine and 3'-phosphoadenosine 5'-phosphateBiochem. Biophys. Res. Commun. v335, p.417-423 |
| 58509 | 5PAH | Erlandsen H, Flatmark T, Stevens RC, Hough ECrystallographic analysis of the human phenylalanine hydroxylase catalytic domain with bound catechol inhibitors at 2.0 A resolutionBiochemistry v37, p.15638-15646 |
| 65041 | 2QMZ | Fu Y, Buryanovskyy L, Zhang Z, 2007/7/17 |
| 65825 | 2VQ5 | Ilari A, Franceschini S, Bonamore A, Boffi A, 2008/3/11 |
Physical Property Value Units Temp (deg C) Source |Melting Point |128 |deg C |EXP |- |pKa Dissociation Constant |8.93 |(none) |EXP |- |log P (octanol-water) |-0.98 |(none) |EXP |- |Water Solubility |1.00E+06 |mg/L |25 |EST |- |Vapor Pressure |2.57E-05 |mm Hg |25 |EST |- |Henry's Law Constant |8.79E-15 |atm-m3/mole |25 |EST |- |Atmospheric OH Rate Constant |9.01E-11 |cm3/molecule-sec |25 |EST |- |} Organism Test Type Route Reported Dose (Normalized Dose) Effect Source |mammal (species unspecified) |LD50 |unreported |1120mg/kg (1120mg/kg) |Khimiko-Farmatsevticheskii Zhurnal. Chemical Pharmaceutical Journal. For English translation, see PCJOAU. Vol. 24(4), Pg. 42, 1990. |- |mouse |LD50 |intracervical |74mg/kg (74mg/kg) |BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY) |Tohoku Yakka Daigaku Kenkyu Nempo. Annual Report of the Tohoku College of Pharmacy. Vol. 27, Pg. 131, 1980. |- |mouse |LD50 |intraperitoneal |950mg/kg (950mg/kg) |SENSE ORGANS AND SPECIAL SENSES: OTHER CHANGES: OLFACTION
LUNGS, THORAX, OR RESPIRATION: RESPIRATORY STIMULATION
BLOOD: HEMORRHAGE |Oyo Yakuri. Pharmacometrics. Vol. 8, Pg. 835, 1974. |- |mouse |LD50 |intravenous |59mg/kg (59mg/kg) |SENSE ORGANS AND SPECIAL SENSES: OTHER CHANGES: OLFACTION
LUNGS, THORAX, OR RESPIRATION: RESPIRATORY STIMULATION
BLOOD: HEMORRHAGE |Oyo Yakuri. Pharmacometrics. Vol. 8, Pg. 835, 1974. |- |rat |LD50 |intraperitoneal |163mg/kg (163mg/kg) |LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES
KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)" |Toxicology and Applied Pharmacology. Vol. 88, Pg. 433, 1987. |- |}
